The Clinical Trial Service Unit and Epidemiological Studies Unit, where the collaboration's secretariat is located, reported involvement in clinical trials of cholesterol modification therapy and of antiplatelet therapy with funding from the Medical Research Council, British Heart Foundation, and companies including Bayer, Merck, Merck Schering Plough, Solvay and the Aspirin Foundation.